Advertisement
Advertisement
PHAR
Pharming Group N.V. ADS, each representing 10 ordinary shares
10.77
USDSponsored
-0.49
-4.40%
Sep 23, 15:46 UTC -4
Open
PHAR Earnings Reports
Positive Surprise Ratio
PHAR beat 20 of 42 last estimates.
48%
Next Report
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$111.34M
/$0.02
Implied change from Q2 26 (Revenue/ EPS)
+23.44%
/--
Implied change from Q3 25 (Revenue/ EPS)
+14.43%
/+100.00%
Pharming Group N.V. ADS, each representing 10 ordinary shares earnings per share and revenue
On Jul 30, 2026, PHAR reported earnings of 0.00 USD per share (EPS) for Q2 26, missing the estimate of 0.02 USD, resulting in a -90.05% surprise. Revenue reached 90.20 million, compared to an expected 103.64 million, with a -12.97% difference. The market reacted with a -10.49% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 4 analysts forecast an EPS of 0.02 USD, with revenue projected to reach 111.34 million USD, implying an -- of --% EPS, and increase of 23.44% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
AnaptysBio, Inc. Common Stock
Report Date
Sep 21, 2026 For Q2 26
Estimate
$0.00
Actual
$5.11
Surprise
>+10,000.00%
BlossomHill Therapeutics, Inc. Common Stock
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$1.03
Actual
-$8.75
Surprise
-746.56%
Vogenx Inc Common Stock
Report Date
Sep 17, 2026 For Q2 26
Estimate
-$0.07
Actual
-$0.07
Surprise
+1.96%
Benitec Biopharma Inc. Common Stock
Report Date
Sep 14, 2026 For Q4 26
Estimate
-$0.27
Actual
-$0.26
Surprise
+5.59%
Anixa Biosciences, Inc.
Report Date
Sep 09, 2026 For Q3 26
Estimate
-$0.08
Actual
-$0.08
Surprise
+8.78%
Abivax SA - ADR
Report Date
Sep 21, 2026 For Q2 26
Estimate
-$1.82
Actual
-$2.09
Surprise
-14.47%
AYTU BioPharma, Inc. Common Stock
Report Date
Sep 22, 2026 For Q4 26
Estimate
-$0.33
Actual
-$0.05
Surprise
+84.92%
Neuphoria Therapeutics Inc. Common Stock
Report Date
Sep 18, 2026 For Q4 26
Estimate
-$0.57
Actual
-$0.95
Surprise
-66.32%
NewcelX Ltd. Ordinary Shares
Report Date
Sep 18, 2026 For Q2 26
Estimate
-$0.54
Actual
-$0.96
Surprise
-77.58%
Alzamend Neuro, Inc. Common Stock
Report Date
Sep 10, 2026 For Q1 27
Estimate
-$0.57
Actual
-$0.68
Surprise
-19.05%
FAQ
What were Pharming Group N.V. ADS, each representing 10 ordinary shares's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Pharming Group N.V. ADS, each representing 10 ordinary shares reported EPS of $0.00, missing estimates by -90.05%, and revenue of $90.20M, -12.97% below expectations.
How did the market react to Pharming Group N.V. ADS, each representing 10 ordinary shares's Q2 2026 earnings?
The stock price moved down -10.49%, changed from $12.01 before the earnings release to $10.75 the day after.
When is Pharming Group N.V. ADS, each representing 10 ordinary shares expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Pharming Group N.V. ADS, each representing 10 ordinary shares's next earnings report?
Based on 4
analysts, Pharming Group N.V. ADS, each representing 10 ordinary shares is expected to report EPS of $0.02 and revenue of $111.34M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.